论文部分内容阅读
[目的]探讨卡培他滨联合放疗对直肠癌的疗效影响。[方法]将我院2008年7月～2010年8月收治的82例直肠癌患者随机分为对照组和治疗组。对照组40例采用卡培他滨单药治疗,治疗组42例采用卡培他滨联合放疗治疗。比较两组患者的临床疗效、生存时间、1年和2年生存率以及不良反应发生情况,并进行统计分析。[结果]治疗组客观有效率为30.9%高于对照组的12.5%,差异有统计学意义(P﹤0.05);治疗组疾病控制率达78.6%,明显高于对照组的57.5%,差异有统计学意义(P﹤0.05);治疗组的生存时间、1、2年生存率均高于对照组,差异有统计学意义(P﹤0.05)。[结论]卡培他滨联合放疗治疗直肠癌效果优于单一的卡培他滨治疗,值得推广应用。
[Objective] To investigate the curative effect of capecitabine combined with radiotherapy on rectal cancer. [Methods] 82 cases of rectal cancer admitted to our hospital from July 2008 to August 2010 were randomly divided into control group and treatment group. Forty cases in the control group were treated with capecitabine monotherapy, and 42 cases in the treatment group were treated with capecitabine combined with radiotherapy. The clinical efficacy, survival time, 1-year and 2-year survival rates and adverse reactions of the two groups were compared and statistically analyzed. [Results] The objective effective rate in the treatment group was 30.9%, which was significantly higher than that in the control group (12.5%), the difference was statistically significant (P <0.05). The disease control rate in the treatment group was 78.6%, significantly higher than that in the control group (57.5% (P <0.05). The survival time and the 1-year and 2-year survival rates of the treatment group were significantly higher than those of the control group (P <0.05). [Conclusion] Capecitabine combined with radiotherapy is superior to single capecitabine in the treatment of rectal cancer, which is worth popularizing and applying.